Fund moves
From a 13F filed Feb 13, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SPRB · NASDAQ · Pharmaceutical Preparations
Spruce Biosciences (SPRB) · oqro.io/stocks/SPRB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$38.00−2.49 (−6.15%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Spruce Biosciences was filed in the last 90 days. The latest on record was on Oct 9, 2025.
Since 2020, Spruce Biosciences insiders reported 11 open-market purchases and 10 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2025.
No open-market sale by an insider of Spruce Biosciences (SPRB) was filed with the SEC in the last 90 days.
No trade in Spruce Biosciences (SPRB) was disclosed by a member of Congress in the last 12 months.
Spruce Biosciences's next results are expected on Mar 8, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−63.0% (−$64.61) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $102.61 on Nov 20, 2025 to $38.00 on Nov 20, 2026 (−63.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in South San Francisco, Ca.
Last 12 months
−63.0%
Market value
$121M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 531K shares sold short (16.6% of shares outstanding), +1.8% vs the previous count, 7.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$0
−100.0% vs the year before
Net income, fiscal 2025
−$39M
A loss for the year
Shares outstanding
2.87M
As of Nov 5, 2026
Fund moves
From a 13F filed Feb 13, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
2 tracked managers disclosed the same change for Q3 2025. Among this manager's largest new positions for Q3 2025.
Insider buying
9 days before an 8-KTraded Oct 6, 2025 · filed 3 days later
Since the trade −70.9% · S&P 500 +2.7% · to Nov 20
Bought at the 52-week high, RSI 97, 595% above its 200-day average
A major shareholder of Spruce Biosciences paid $4.6K out of pocket for Spruce Biosciences shares. Shares held went up 24% with this purchase.
Traded Oct 6, 2025 · largest single transaction ~$4.5KNot reported under a pre-arranged trading plan
Oct 6, 2025~$4.5K · 232 sh @ $19.33
DetailsOfficial recordOct 6, 2025~$436 · 25 sh @ $17.46
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Spruce Biosciences over the 12 months to Nov 19, 2026: 1 clinical trial.
Insiders of Spruce Biosciences reported 11 open-market purchases and 10 sales since 2020; purchases in 3 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $4.6K1×1 trade | $4.9K2×2 trades |
| 2024 | — | $3.41M5×5 trades |
| 2023 | $9M2×2 trades | — |
| 2021 | — | $6.83M3×3 trades |
| 2020 | $29.3M8×8 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Latest annual report filed Mar 9, 2026, compared with the one filed Apr 15, 2025. Read the filing
In January 2025, Neurocrine Biosciences, Inc. (“Neurocrine”) initiated proceedings seeking to invalidate European Patent 3,784,233 (the “Patent”) in the United Kingdom Patents Court (“UKPC”), and in August 2025, initiated similar proceeds before the Unified Patent Court (collectively, the “Patent Proceedings”). In February 2026, the UKPC issued a judgment ordering us to pay Neurocrine an interim payment of approximately $1.2 million for its legal costs. As of the year ended December 31, 2025, we accrued $1.9 million for loss contingencies associated with the Patent Proceedings.
Source: SEC EDGAR, Form 10-K filed Mar 9, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
1 active phase 3 trial and 0 active phase 2 trials led by this company, mostly in mps iiib. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
0 certified in FY2026 Q3, vs 0 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Revenue
—
Year earlier: $0
Free cash flow, last 12 months
−$13.8M
This quarter −$13.8M, a year earlier −$5.32M
Net cash
$68.2M
Debt $19.5M, cash $87.7M, at Sep 30, 2026
Net income, last 12 months
−$67.1M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 9, 2026.
Revenue and earnings history, 7 fiscal yearsEarnings dates and the stock's moves
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 5,000 words.
We are a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. We have a diverse portfolio of product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. We were founded in April 2016 and are led by a management team experienced in the development and commercialization of groundbreaking therapeutics.
And 8 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 9, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 34.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (25.7% on ATS, 9.1% with other brokers), close to its 26-week average of 32.9%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: MS POOL (ATS-4) (18.8%), UBS ATS (17.8%), INSTINCT X (8.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Last results
Nov 9, 2026
Within the 30 days after it, until Dec 9, 2026
Next results, expected
Mar 8, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Spruce Biosciences's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Spruce Biosciences's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.